INmune Bio (NASDAQ:INMB – Get Free Report) and Candel Therapeutics (NASDAQ:CADL – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk and analyst recommendations.
Volatility and Risk
INmune Bio has a beta of 1.78, meaning that its share price is 78% more volatile than the S&P 500. Comparatively, Candel Therapeutics has a beta of -1.2, meaning that its share price is 220% less volatile than the S&P 500.
Earnings and Valuation
This table compares INmune Bio and Candel Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| INmune Bio | $42,000.00 | 2,898.20 | -$30.01 million | ($2.18) | -2.52 |
| Candel Therapeutics | $120,000.00 | 2,213.78 | -$37.94 million | ($1.73) | -4.73 |
Profitability
This table compares INmune Bio and Candel Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| INmune Bio | -26,333.59% | -117.48% | -78.96% |
| Candel Therapeutics | N/A | -629.29% | -173.39% |
Institutional & Insider Ownership
12.7% of INmune Bio shares are owned by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are owned by institutional investors. 35.2% of INmune Bio shares are owned by company insiders. Comparatively, 41.6% of Candel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Analyst Ratings
This is a summary of recent recommendations for INmune Bio and Candel Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| INmune Bio | 0 | 0 | 3 | 0 | 3.00 |
| Candel Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
INmune Bio presently has a consensus price target of $20.00, indicating a potential upside of 264.30%. Candel Therapeutics has a consensus price target of $19.00, indicating a potential upside of 132.27%. Given INmune Bio’s higher possible upside, equities research analysts plainly believe INmune Bio is more favorable than Candel Therapeutics.
Summary
INmune Bio beats Candel Therapeutics on 8 of the 13 factors compared between the two stocks.
About INmune Bio
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
About Candel Therapeutics
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.
